STOCKS TELEGRAPH

Tag: Nasdaq

  • Why is Floki Inu (FLOKI) Trending?

    Why is Floki Inu (FLOKI) Trending?

    Floki stunned the crypto world in 2021 with a forceful, worldwide showcasing effort that crossed landmasses and highlighted associations with significant football clubs and Formula 1’s Alfa Romeo group. In less than a half year, Floki arose out of a rough beginning to turn into a main 70 crypto project by market cap at USD 3.5b, prior to amending with the worldwide slump in values and crypto.

    The Floki Team and Vikings achieved this through a remarkable mix of brilliant tokenomics, image and assault culture, broad showcasing, associations with market creator Wintermute, DeFi convention Inverse Finance, and a pledge to noble cause supported by genuine effect. Floki broadly worked together with Kimbal Musk’s Millions Gardens Movement and gave USD 1.4m to assist the association with battling food uncertainty and simply this May (2022) finished a magnanimous school project in Nigeria in organization with the Tabitha Cumi Foundation.

    The Floki undertaking’s environment incorporates local area, schooling, DeFi, and a self-assured move into metaverse gaming, which has started to build up some momentum and gain the consideration of major monetary media sources like NASDAQ.com.

    The Road to Valhalla

    In 2021 the Floki Team announced their aim to disturb probably the most sultry area in crypto: play-to-acquire metaverse gaming. The game is called Valhalla, and an Alpha form of the Battle Arena piece of the game was delivered for testing early this year and opened to the public simply this May of 2022. The nature of the interactivity and speed of improvement has quieted the doubters and drawn in the consideration of major web-based outlets.

    The Floki and Valhalla groups have an early advantage in this intensely hot, creating area of crypto. The popular Floki Community (called the Floki Vikings) has drawn in with Valhalla throughout recent months to take part in its advancement through bug testing and criticism, and new fixes and “breaks” are delivered consistently.

    Floki Conquers the Metaverse

    Floki’s move into the metaverse is no little matter, as the task hopes to recuperate its past market cap against a generational decline in the business sectors.

    It additionally helps that one of the greatest tech organizations worldwide, Meta, is wagering on the metaverse, in any event, venturing to such an extreme as to change its name from Facebook. The organization purportedly spent USD 10 billion on its metaverse project last year, calling it the eventual fate of innovation. Digital currencies and blockchain will assume an imperative part in that excursion.

    The potential for inventive, little cap undertakings to upset this space is clear. Savvy crypto-financial backers are giving close consideration to the metaverse play, and Floki is ready to profit from this pattern in a significant manner.

    The authority delivery date for Valhalla presently can’t seem to be declared, yet most would agree this declaration will blow some people’s minds all through crypto and then some. Those intrigued can as of now test a piece of Valhalla to perceive what it looks like and plays contrasted with other play-to-acquire games.

  • Iterum Therapeutics plc (ITRM) stock drops in Pre-Market today : Here’s to know why

    Shares of the Iterum Therapeutics plc (ITRM) stock were dropping in the pre-market trading session today on July 28, 2021, after rising to a good height in the last trade. ITRM stock price saw a decline of 6.88% to drop at $0.69 a share at the time of this writing. The penny stock went high by 17.53% at the previous closing. Let’s try to figure out the reason behind this fall.

    What’s Happening?

    Iterum Therapeutics plc is the clinical-stage biotechnology stock that develops anti-infectives to treat infectious diseases that cause due to multi-drug resistant pathogens.  ITRM stock is falling in pre-market today despite any obvious reason related to it. No specific news or announcement in today’s date is available to justify the bearish sentiment. ITRM stock dropped 68.73% in the last 30 days and in the past 12 months, the penny stock dropped by 32.64%. Let’s take a look at some recent events of the Iterum.

    ITRM stock received Response Letter from FDA:

    Iterum stock received a complete response letter(CRL) from U.S Food and Drug Administration for its new drug application(NDA) oral sulopenem on July 23, 2021. The FDA did not approve the new drug application in its present form. According to CRL, FDA acknowledged the significant statistical data of the overall response rate of the oral sulopenem against ciprofloxacin in the population resistant to ciprofloxacin. However, FDA mentioned in the CRL that this data is not sufficient and demanded additional data for the approval of the drug.

    FDA recommendations to ITRM stock:

    The FDA recommended Iterum stock to conduct at least one more well-controlled and adequate clinical trial by using a different comparator drug. Moreover, the recommendations also included a nonclinical investigation of the NDA in order to determine the optimal dose prescription. However, this recommendation was not connected with approvability of the drug.

    Financial View of ITRM stock:

    According to the first quarter 2021 financial results, Iterum stock suffered a net loss of  $98.9 million as compared to a $16.1 million net loss in the same quarter of the prior year. The penny stock spent $2.5 million and $3.4 million in R&D expenses and general and administrative expenses respectively. At the end of the first quarter, Iterum had $100.5 million in cash, cash equivalents, and short-term investments.

    Wrap Up:

    The penny stock is now red in Wednesday’s pre-market trading session after a strong gain in the last trade. ITRM stock has a market cap of 132.7 million and a 13,786,501 average trading volume.

  • Why is TAL Education Group (TAL) stock rising in pre-market today?

    Shares of the TAL Education Group (TAL) stock were rising in the pre-market trading session today on July 27, 2021, after seeing a major drop yesterday due to the widening of the official crackdown by the Chinese government against for-profit education companies. TAL stock price saw a push of 9.09% to reach $4.80 a share as of this writing. The stock dropped by 26.67% at the previous closing. Let’s discuss more of it.

    What’s Happening?

    TAL Education Group offers K-12 after-school tutoring services to students in the People’s Republic of China. There is no specific news related to TAL stock in today’s date to support today’s bullish sentiment. On the other hand, the Chinese government yesterday announced an extended overhaul for its education sector in order to decrease the education expenses for Chinese families.

    New Rules:

    According to the new rules of Chinese regulators, the Chinese tutoring stock will have to become a non-profit for their survival. They would have no right to generate capital in the stock market and would not be able to invest in any other education-providing entity. Moreover no, new licenses would be granted as mentioned in the official document.

    TAL stock Reaction on new Rules:

    TAL Education will comply with all the rules and regulations that Chinese regulators are imposing on the education sector. However, the management of TAL stock said that the new rules will adversely affect its after-school tutoring services. This would ultimately significantly impact TAL stock’s operations and prospects.

    Analyst View on TAL stock:

    The Goldman Sachs analyst Christine Chao in response to these rules downgraded TAL stock from buy to neutral. Bank of America analyst Lucy Yu downgraded from buy to underperform after the new rules surfaced.

    Conclusion:

    After facing a major drop in the previous trading following the announcement of new rules for the Chinese for-profit education sector, TAL Education stock is climbing again in today’s pre-market. However, things don’t seem to be favorable for Chinese education stocks. The management is looking for possible ways to comply with new rules and regulations. In a nutshell, investors need to be cautious before adding this stock to their portfolio. 

  • Why Tyme Technologies, Inc. (TYME) stock is moving high today?

    Tyme Technologies, Inc. (TYME) stock announced the receival of notification from the United States Patent and Trademark Office that states the grant of additional patent claims regarding Tyme’s metabolomic technology platform. The TYME stock price saw a push of 38.89% to reach $1.50 a share as of this writing. The stock was gloomy at the previous trading session and went down by 2.70%. Let’s deep dive to explore more of it.

    What’s Happening?

    Tyme Technologies, Inc is the biotechnology stock focused on the development of therapeutics related to cancer metabolism in the United States of America. The U.S patent no 11,058,638 which the TYME stock has been granted is related to the delivery of therapeutics to the targeted cancer cells.

    TYME stock Technology:

    The technology of the Tyme Technologies works in such a manner that the tyrosine isomer racemetyrosine fuses a second therapeutic agent in order to create a fusion compound that allows the targeted delivery to cancer cells in a novel manner. This delivery method affirms the metabolic phenomenon in which the cancer cells grow by consuming a high quantity of non-essential amino acids, in which tyrosine is also included. These cancer cells get non-essential amino acids from their surrounding as they themselves cannot make enough of these i.e., amino acids.

    This delivery technology requires further studies which TYME stock is planning to start this year. As it is the investigational procedure of drug delivery in the pre-clinical phase, it is not approved by the U.S for any disease indication.

    TYME stock’s Chief Scientific Officer Remarks:

    The Chief Scientific Officer of the TYME stock considered the delivery technology as the opportunity for Tyme Technologies for the expansion of TYME’s current cancer-metabolism-based approach with a drug delivery platform. He emphasized that this technology would help in the improvement of safety and efficacy of the wide range of anticancer drugs.

    Conclusion:

    Investors are responding to the recent news related to the U.S patent which TYME stock did announce today. The stock is bullish today and the trading volume is well above the average. The delivery technology of TYME is in the early stages but it can leverage itself in the future.

  • Why is UP Fintech Holding Limited (TIGR) stock dropping today?

    Shares of the UP Fintech Holding Limited (TIGR) stock were dropping today in the pre-market trading session despite the absence of any specific news related to it. TIGR stock price saw a downtrend of 8.89% to drop at $15.38 a share as of this writing. The stock was also gloomy at the previous trading session and went down by 6.59% at closing. Let’s take a look at this stock in detail.

    What’s Happening?

    UP Fintech Holding Limited (TIGR) stock is an online brokerage service provider that mainly focuses on Chinese investors. The stock is dropping for the second consecutive day. There seems to be no major culprit behind the falling stock price of TIGR stock in today’s date. No press release or earnings report has been released in recent days to justify the bearish sentiment. However, on July 14, 2021, Goldman raised the price target for TIGR stock to “a sell”.

    TIGR Stock Subsidiary News:

    About a month ago, UP Fintech’s Singapore subsidiary Tiger Brokers (Singapore) Pte. Ltd (TBSPL) did receive approval-in-principle related to the trading of securities and clearing members in Singapore. TBSPL was admitted as a Clearing Member of The Central Depository (Pte) Limited in connection with approval. Furthermore, it was also approved as the trading member by Singapore Exchange Securities Trading Limited and Singapore Exchange Derivatives Trading Limited. The approval paved the way for TBSPL to strengthen its position in Singapore.

    TIGR Stock Follow On Public Offering:

    On June 11, 2021, UP Fintech stock did announce the closing of its previously announced public offering of 6.5 million American Depository Shares(ADSs). Each ADS represented 15 class A ordinary shares of common stock and the offering price was US$24.50 per ADS. The underwriters were granted a 30-day option to buy 975,000 additional ADSs of the TIGR stock under the same public offering price. This option of buying additional shares had been fully exercised by underwriters.

    The net proceeds resulted from this offering were intended to use in the expansion of TIGR’s customer base along with increasing customer engagement via its services. Moreover, part of the proceeds is specified for development in products, services, and technology areas. The TIGR stock also used these proceeds to expand its international presence.

    Conclusion:

    TIGR stock is dropping in the stock market despite no obvious reason or specific news related to it. The next earnings report is expected in the mid of August. It is to be noted that this stock’s full-year 2020 revenue was 136.1% higher than the full-year revenue of 2019.

  • Riot Blockchain, Inc. (RIOT) stock rises in the Pre-market today: Why is it so?

    Shares of the Riot Blockchain, Inc. (RIOT) were rising in the pre-market trading session today on April 26, 2021, after rising as much as 5.45% at closing. RIOT price saw a surge of 8.11% to reach $41.6 a share as of this writing. It seems that the RIOT stock is moving high without any particular reason. Let’s deep dive to explore more of it.

    What’s happening?

    There is no specific news or earnings report by the RIOT to explain the reason behind the rally. We find no signs of analyst upgrades or increased per-share price of the RIOT to justify the rising RIOT Stock price. This is spreading curiosity among individuals eying on Riot Blockchain. Now it is better to analyze some of the past activities of RIOT stock.

    Recent Developments:

    On April 08, 2021. Riot stock entered into the definitive agreement with Whinstone US, Inc (“Whinstone”), pursuant to which Whinstone along with all its assets and operation will be acquired by the RIOT. The transaction value for this deal totaled approximately $651 million based on the per-share price of $48.37 of RIOT stock at that time.

    On April 06, 2021, RIOT stock did announce the appointments of Megan Brooks, Phil McPherson, and Ryan Werner for the positions of Chief Operating Officer, Vice President, Capital Markets, and Vice President, Finance respectively in order to support the substantial progress which RIOT is making as a result of its strategic initiatives.

    RIOT stock production in March 2021:

    On April 12, 2021, RIOT stock did announce the March production and its operation updates according to which Riot Blockchain produced 187 BTC, which represents an increase of 80% as compared to 104 BTC in March 2020.BTC production in the first quarter of 2021 rose by 75% to reach 491 BTC as compared to the production of  281 BTC in the first quarter of 2020.

    Conclusion:

    Things are going well for RIOT stock as far as market sentiment is concerned without any recent news related to it. The previous developments show that the Riot Blockchain is growing over time. In a nutshell, investors need to keep an eye on this stock.

  • 111, Inc. (YI) stock rises in the Pre-market today: What’s going on?

    111, Inc. (YI) stock rises in the Pre-market today: What’s going on?

    Shares of 111, Inc. (YI) stock were continuing the rising momentum in the pre-market trading session after recording the gain of 0.91% at the previous closing. YI stock surged by 8.84% to reach $12.07 a share at the time of this writing. Let’s see the reason behind this bull.

    What’s happening?

    It seems that momentum has been built for YI in the previous market despite the lack of particular news by the YI stock today or not even in this month. Also, there are no signs of analyst upgrade or upswing per share targeted price of the YI to justify the bull. Here are some previous recent activities by the YI stock.

    YI partnership with Jianming Pharmaceutical

    On March 25, 2021, YI announced the strategic cooperation agreement with Jianming Pharmaceutical for the development of an online chronic disease management platform. The purpose of developing this platform for Jianming Pharmaceuticals was to treat hepatobiliary diseases in China by offering and distributing Jianming Pharmaceutical’sliver and gallbladder medications to the patients initially in Fujian province and then to the whole country.

    Financial Results of YI stock:

    On March 18, 2021, YI announced its unaudited fourth quarter and fiscal year results of 2020 pursuant to which YI stock generated RMB2.64 billion revenue with a 96.1% increase year over year. The gross profit of YI in the fourth quarter surged by 143.7% to reach RMB103.6 million as compared to the same period of the prior year. Operating expenses in the fourth quarter for YI were RMB248.3 million representing a 17.9% YoY increase.

    Total revenue for the fiscal year 2020 of YI was  RMB8.20 billion which is 107.6% higher than the revenue of the previous year. Gross profit of RMB365.8 million showed 121.5% yearly improvement. Operating expenses for the whole year were RMB839.1 million with a 27.4% YoY increase.

    Conclusion:

    YI stock has been hot among the investors as its stock price is continuously rising despite the absence of any news by the 111, Inc. Recent developments point to the overall growth of the stock, and a recent earning report proved that the YI stock has shown significant growth over the year. In a nutshell, YI stock can be a good bet for investors in the long run.

  • Coinbase (COIN): To Go Up or Crash?

    Coinbase (COIN): To Go Up or Crash?

    One of the most sought-after listing – if not the most – occurred yesterday and as the market have settled there are mixed views about the future of Coinbase. Coinbase’s listing is indicative of widespread cryptocurrency acceptance. The crypto market surged upward with Bitcoin establishing a new all-time high with the direct listing of Coinbase.

    Coinbase got a reference price of $250 from NASDAQ but the opening price was much higher – at $380 – giving it a valuation of around $100 billion. In the initial hours of trading, the price of the ticker COIN shot up to $420. However, COIN could not sustain the high price and quickly fell to as low as $310. At the time of publication, COIN stands at a price of $328.

    On Bitfinex and FTX the pre-IPO tokenized price of COIN was at $610, which has fallen, too, to $410. It appears as though the enthusiasm for Coinbase’s COIN has died down. While some investors have grown less and less bullish on COIN, others continue to vie for it.

    MoffettNathanson analyst Lisa Ellis has regarded COIN as one of the must-have stocks. The cryptocurrency market is going to propel COIN upwards and COIN is going to push cryptocurrencies up – creating a positive feedback loop. Per the analyst, the stock is poised to reach $600 in the coming days.

  • Coinbase’s reference price of 0 lower than expectations

    Coinbase’s reference price of $250 lower than expectations

    The leading cryptocurrency exchange Coinbase is all set to be listed on NASDAQ. The cryptocurrency world is holding its breath for Coinbase’s direct listing. Coinbase is the first significant direct listing on NASDAQ.

    Coinbase’s ticker COIN received a reference price of just $250 which is much lower than the expectation. However, the direct listing means the reference price is not an indicator of Coinbase’s market capitalization. The reference price of $250 signifies a valuation of $65 billion whereas estimates range anywhere from $68 billion to $120 billion.

    The NASDAQ announcement was quick to point out that the reference price does not indicate the offering price and that no trade has taken place at the price of $250. The reference price had been decided with the consultation of Coinbase and while keeping its transaction history. The opening price will be determined by the sell and buy orders in the auction.

    Coinbase has also surprised its full-time employees with 100 shares each. The current reference price makes it $25,000 per employee of the 1,700 workforce of Coinbase. This was a “thank you” gesture from Coinbase and employees can sell their shares immediately after Coinbase goes public.

    The Coinbase NASDAQ listing is one of the most anticipated events and other major crypto exchanges are set to follow if the listing and opening price surpass expectations. Kraken, a Coinbase competitor, has already hinted towards their stock exchange listing as well which may happen in 2022.

  • Universe Pharmaceuticals (UPC) stock is rising today: Things you need to know

    Universe Pharmaceuticals (UPC) stock is rising today: Things you need to know

    Shares of Universe Pharmaceuticals (UPC) stock were rising today in response to the announcement of the full exercise of Underwriter’s over-allotment option by Univest Securities, LLC for its client Pharmaceuticals INC. UPC stock price saw a push of 28.68% to reach $5.16 a share at the time of this writing. At the previous trading session, UPC stock was red and closed with an 8.24% drop. Let’s deep dive to explore more of it.

    What’s happening?

    Today’s news about the UPC stock explains that Univest Securities, LLC has exercised in full of its Underwriter’s over-allotment option to purchase 750,000  additional shares of its common stock for its client Universe Pharmaceuticals INC. The public offering price for this offering was $5.00 per share and it resulted in the additional gross proceeds worth $3.75 million. Now the total number of sold shares of UPC stock in this offering reached  5.75 million and gross proceeds surged to $28.75 million. Back on March  26, 2021,  Univest closed the initial public offering for its client Universe Pharmaceuticals of 5 million shares of its common stock which was previously announced on March 23, 2021.

    Use of Proceeds:

    UPC stock has the plan to use proceeds from this offering in the advancement of manufacturing facilities as well as for research and development purposes. Part of these proceeds will be used for marketing, branding, general and other cooperate purposes.

    About UPC stock:

    Universe Pharmaceuticals INC (UPC), a subsidiary of Sununion Holding Group Limited, is the manufacturer, marketer, distributor, and seller of traditional Chinese medicine products in the Republic of China.UPC’s core focus is to cure elders suffering from various chronic diseases. Furthermore, UPC  is also the seller of third-party producer’s products including biomedical drugs, medical instruments as well as traditional Chinese medicine products.UPC was founded in 2019 and is in Jiangxi, China.

    Conclusion

    Investors are responding to the news announced by the UPC stock, but no one knows how long this trend will continue. Proceeds from the offering will help Universe Pharmaceutical in its various operational as well as marketing areas. In a nutshell, investors having long-term prospects need to do analyze UPC fundamentals, balance sheet, and development prospects before adding them to their portfolio.